Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE)
FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis
Sponsor: Adare Pharmaceuticals, Inc.
Listed as NCT03191864, this PHASE2 trial focuses on Eosinophilic Esophagitis and remains completed. Sponsored by Adare Pharmaceuticals, Inc., it has been updated 17 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — May 2023 [monthly]
Completed PHASE2
▶ Show 12 earlier versions
-
Mar 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adare Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .